Browse CHMP5

Summary
SymbolCHMP5
Namecharged multivesicular body protein 5
Aliases HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytosol. Endosome membrane Peripheral membrane protein Note=Localizes to the midbody of dividing cells. Localized in two distinct rings on either side of the Fleming body.
Domain PF03357 Snf7
Function

Probable peripherally associated component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV-1 p6- and p9-dependent virus release.

> Gene Ontology
 
Biological Process GO:0000070 mitotic sister chromatid segregation
GO:0000226 microtubule cytoskeleton organization
GO:0000819 sister chromatid segregation
GO:0000920 cell separation after cytokinesis
GO:0001881 receptor recycling
GO:0001919 regulation of receptor recycling
GO:0006900 membrane budding
GO:0006997 nucleus organization
GO:0007032 endosome organization
GO:0007033 vacuole organization
GO:0007034 vacuolar transport
GO:0007040 lysosome organization
GO:0007041 lysosomal transport
GO:0007051 spindle organization
GO:0007059 chromosome segregation
GO:0007067 mitotic nuclear division
GO:0007080 mitotic metaphase plate congression
GO:0007088 regulation of mitotic nuclear division
GO:0007098 centrosome cycle
GO:0007346 regulation of mitotic cell cycle
GO:0008333 endosome to lysosome transport
GO:0010824 regulation of centrosome duplication
GO:0016050 vesicle organization
GO:0016197 endosomal transport
GO:0019058 viral life cycle
GO:0019068 virion assembly
GO:0031023 microtubule organizing center organization
GO:0032886 regulation of microtubule-based process
GO:0032984 macromolecular complex disassembly
GO:0036257 multivesicular body organization
GO:0036258 multivesicular body assembly
GO:0043112 receptor metabolic process
GO:0043241 protein complex disassembly
GO:0044803 multi-organism membrane organization
GO:0046605 regulation of centrosome cycle
GO:0046755 viral budding
GO:0050000 chromosome localization
GO:0051225 spindle assembly
GO:0051297 centrosome organization
GO:0051298 centrosome duplication
GO:0051303 establishment of chromosome localization
GO:0051310 metaphase plate congression
GO:0051493 regulation of cytoskeleton organization
GO:0051640 organelle localization
GO:0051656 establishment of organelle localization
GO:0051783 regulation of nuclear division
GO:0070507 regulation of microtubule cytoskeleton organization
GO:0071985 multivesicular body sorting pathway
GO:0080171 lytic vacuole organization
GO:0090169 regulation of spindle assembly
GO:0090224 regulation of spindle organization
GO:0090307 mitotic spindle assembly
GO:0098813 nuclear chromosome segregation
GO:1901673 regulation of mitotic spindle assembly
GO:1902115 regulation of organelle assembly
GO:1902590 multi-organism organelle organization
GO:1902592 multi-organism membrane budding
GO:1902850 microtubule cytoskeleton organization involved in mitosis
GO:1904896 ESCRT complex disassembly
GO:1904903 ESCRT III complex disassembly
Molecular Function GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0005913 cell-cell adherens junction
GO:0010008 endosome membrane
GO:0044440 endosomal part
> KEGG and Reactome Pathway
 
KEGG hsa04144 Endocytosis
Reactome R-HSA-162588: Budding and maturation of HIV virion
R-HSA-1643685: Disease
R-HSA-917729: Endosomal Sorting Complex Required For Transport (ESCRT)
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-5663205: Infectious disease
R-HSA-162599: Late Phase of HIV Life Cycle
R-HSA-199991: Membrane Trafficking
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolCHMP5
Namecharged multivesicular body protein 5
Aliases HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CHMP5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCHMP5
Namecharged multivesicular body protein 5
Aliases HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CHMP5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.82; FDR: 0.00700 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCHMP5
Namecharged multivesicular body protein 5
Aliases HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CHMP5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2220.348
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3530.886
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1280.943
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2570.433
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0190.99
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5620.773
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1570.721
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1480.935
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1760.931
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1840.926
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1240.967
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1620.0229
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CHMP5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCHMP5
Namecharged multivesicular body protein 5
Aliases HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CHMP5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCHMP5
Namecharged multivesicular body protein 5
Aliases HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CHMP5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CHMP5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCHMP5
Namecharged multivesicular body protein 5
Aliases HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CHMP5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCHMP5
Namecharged multivesicular body protein 5
Aliases HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CHMP5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCHMP5
Namecharged multivesicular body protein 5
Aliases HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CHMP5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCHMP5
Namecharged multivesicular body protein 5
Aliases HSPC177; CGI-34; Vps60; C9orf83; SNF7DC2; chromosome 9 open reading frame 83; chromatin modifying protein 5; ......
Chromosomal Location9p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CHMP5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.